54741_Image_jpeg.jpg
Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020 on the Value of BVA-100®
September 28, 2020 08:30 ET | Daxor Corporation
NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100® Study in Hospitalized Patients With COVID-19
July 15, 2020 08:00 ET | Daxor Corporation
COVID-19 Investigation Commences at NYU Langone Health with Daxor’s Blood Volume Analysis Technology NEW YORK, July 15, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment...
54741_Image_jpeg.jpg
Daxor Corporation Announces Engagement with Hospitals and Government for Use of the Blood Volume Analyzer (BVA-100®) to Stem COVID-19 Deaths
March 02, 2020 08:00 ET | Daxor Corporation
NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th Congress
February 12, 2020 08:00 ET | Daxor Corporation
New Data Scheduled for Presentation on Daxor’s BVA-100® NEW YORK, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation...
54741_Image_jpeg.jpg
Daxor Corporation Announces the Acquisition of the BVA-100® Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest
August 06, 2019 08:00 ET | Daxor Corporation
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the LD Micro 9th Annual Invitational on June 4th, 2019
May 31, 2019 08:00 ET | Daxor Corporation
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin
January 10, 2019 08:30 ET | Daxor Corporation
NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation of Hypertension
November 13, 2018 08:30 ET | Daxor Corporation
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care
November 07, 2018 08:30 ET | Daxor Corporation
NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients
October 30, 2018 08:30 ET | Daxor Corporation
Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality NEW YORK , Oct. 30, 2018 (GLOBE...